Tom Powles, MBBS, MRCP, MD

Drs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.

A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.

A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

A look at the current unmet needs in front-line renal cell carcinoma treatment.

Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.

Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.

Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.

A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

Brian Shimkus, MD, shares his opinion of data on lenvatinib and pembrolizumab from the CLEAR trial.

Experts discuss how data from the CLEAR trial affects the management of advanced renal cell carcinoma in their clinical practices.

Rana McKay, MD, and Tom Powles, MBBS, MRCP, MD, highlight key data from the CLEAR trial and offer their overall opinions on the combination of lenvatinib plus pembrolizumab for the treatment of renal cell carcinoma [RCC].

Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.

Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”